Research Article
High Thyroglobulin Antibody Levels Increase the Risk of Differentiated Thyroid Carcinoma
Table 2
Clinical characteristics of DTC according to ATAs.
| (a) |
| | | O1 (TPOAb < 50 IU/mL) | O2 (TPOAb ≥ 50 IU/mL) | value |
| | Number () | 207 | 30 | | | Gender (, %) | | | 0.197 | | Male () | 41 (19.8) | 3 (10) | | | Female () | 166 (80.2) | 27 (90) | | | Mean age (yr) | 44.15 ± 12.64 | 38.53 ± 13.50 | 0.025 | | Median TSH (mIU/L) | 1.46 (0.84–2.24) | 2.09 (1.38–3.20) | 0.003 | | Mean nodule size (cm) | 2.71 ± 0.14 | 3.14 ± 0.55 | 0.95 | | Nodule type (, %) | | | 0.718 | | Solitary () | 69 (33.3) | 11 (36.7) | | | Multiple () | 138 (66.7) | 19 (63.3) | | | Lymph node metastasis | 60 (29) | 13 (43.3) | 0.112 | | Extrathyroidal invasion | 42 (20.3) | 6 (20) | 0.971 | | Advanced stages (III, IV) | 75 (36.2) | 15 (50) | 0.146 |
|
|
TSH levels are presented as median (25th–75th empirical percentiles).
DTC: differentiated thyroid cancer.
ATAs: thyroid autoantibodies.
|
| (b) |
| | | G1 (TgAb < 40 IU/mL) | G2 (TgAb ≥ 40 IU/mL) | value |
| | Number () | 181 | 56 | | | Gender (, %) | | | 0.034 | | Male () | 39 (21.5) | 5 (9.9) | | | Female () | 142 (78.5) | 51 (90.1) | | | Mean age (yr) | 44.13 ± 12.20 | 41.23 ± 14.67 | 0.184 | | Median TSH (mIU/L) | 1.44 (0.77–2.30) | 1.72 (1.28–2.57) | 0.018 | | Mean nodule size (cm) | 2.49 ± 0.14 | 3.02 ± 0.31 | 0.07 | | Nodule type (, %) | | | 0.207 | | Solitary () | 65 (35.9) | 15 (26.8) | | | Multiple () | 116 (64.1) | 41 (73.2) | | | Lymph node metastasis | 52 (28.7) | 21 (37.5) | 0.214 | | Extrathyroidal invasion | 31 (17.1) | 17 (30.4) | 0.031 | | Advanced stages (III, IV) | 66 (36.5) | 24 (42.9) | 0.389 |
|
|
TSH levels are presented as median (25th–75th empirical percentiles).
DTC: differentiated thyroid cancer.
ATAs: thyroid autoantibodies.
|
